Below you can find the list of 10 largest generic drug companies. For a detailed coverage of this topic and a more comprehensive list, please see the 21 largest generic drug companies.
Endo is an American generic and specialty medicine company that derives its major sales revenue from the US healthcare system.
9. Stada
Revenue – $2,922 million
Number Of Employees – 10,416
Market Cap –0.432B
TTM $- 1,530.25 million
Germany based company, STADA, specializes in the production of generic and over-the-counter drugs. The company recently signed an exclusive supply agreement with cannabis company MediPharm Labs under which it will distribute medical cannabis products in Germany, and also provide manufacturing, logistics, and regulatory support.
Monkey Business Images/Shutterstock.com
8. Aurobindo Pharma
Revenue – $3,082.45million
Number Of Employees – 18,469
Market Cap –7.0552B
TTM $- 3,263.84 million
The company is an Indian pharmaceutical involved in manufacturing of generics drugs and APIs. The company recently bagged the approval of the US Food and Drug Administration (USFDA) to manufacture and market Dexmedetomidine Hydrochloride in 0.9% sodium chloride injections, a generic version of Hospira’s Precedex.
7. Mallinckrodt
Revenue – $3,162.50million
Number Of Employees – 3,400
Market Cap –15.313M
TTM $- 3,192.50 million
Mallinckrodt is a American-Irish domiciled maker of specialty pharmaceuticals, generic drugs and imaging agents. The company ran into significant issues over the course of the past year, including a bankruptcy being filed against it.
racorn/Shutterstock.com
6. Sun Pharmaceuticals
Revenue – $4,451 million
Number Of Employees – 36,000
Market Cap –18.53 B
TTM $- 4,413million
Indian companies are big on our list, and Sun pharmaceuticals in by far the largest generic drug company in the Indian market and appears in our list of the largest generic drug companies in the world. The company came into existence in the 80s and has gone through several acquisitions and joint ventures to solidify its position in the drugs market.
5. Fresenius
Revenue – $8,380 million
Number Of Employees – 39,627
Market Cap –N/A
TTM $-N/A
While Fresenius is a well-known German company in the pharma and life sciences domain, the company plans to keep strengthening its generic drugs portfolio and business segment through. It has two major acquisitions in plans, one being Akorn, a developer and manufacturer of generic drugs, and secondly the biosimilars segment of Merck KGaA.
wavebreakmedia/Shutterstock.com
4. Sandoz
Revenue – $9,700 million
Number Of Employees – 33,000
Market Cap –N/A
TTM $-N/A
Sandoz is the generic segment of pharma giant Novartis. The segment especially ran into trouble in the past for concerns over pricing of generic drugs dating back to 2011. Novartis is in the process of evaluating these allegations against the division. Sandoz also plans to expand its operations in Japan by acquiring Aspen Pharmacare’s generics business in Japan.
Netherlands global generic giant Mylan has always been one of the strong players in the market. However, as pointed earlier, the company is now part of Pfizer and recently in November 2020, Mylan merged with Pfizer’s generic medicine division Upjohn as spin-off company Viatris was formed.
Definitely one of the market leaders exclusively involved in the generics segment, Teva, produces and markets high quality generics and specialty drugs. The company acquired Allergan’s (NYSE: AGN) generic division in 2015 in a $40.5 billion deal to strengthen its market position.
While Teva has always been considered a leader of the market niche, Pfizer has slowly made its presence in the generics market to top the list of the 21 largest generic drug companies, mainly through strategic acquisitions. Major acquisitions include the buyout of Hospira and more recently the merger with Mylan. Pfizer has steadily built a strong segment of generics in its products, through expertise from the well established segments of these companies.
Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!
It’s the revolution reshaping every industry on the planet.
From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.
Here’s why this is the prime moment to jump on the AI bandwagon:
Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.
Imagine every sector, from healthcare to finance, infused with superhuman intelligence.
We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.
This isn’t a maybe – it’s an inevitability.
Early investors will be the ones positioned to ride the wave of this technological tsunami.
Ground Floor Opportunity: Remember the early days of the internet?
Those who saw the potential of tech giants back then are sitting pretty today.
AI is at a similar inflection point.
We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.
This is your chance to get in before the rockets take off!
Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.
AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.
The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.
As an investor, you want to be on the side of the winners, and AI is the winning ticket.
The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.
From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.
This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.
By investing in AI, you’re essentially backing the future.
The future is powered by artificial intelligence, and the time to invest is NOW.
Don’t be a spectator in this technological revolution.
Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.
This isn’t just about making money – it’s about being part of the future.
So, buckle up and get ready for the ride of your investment life!
Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)
The AI revolution is upon us, and savvy investors stand to make a fortune.
But with so many choices, how do you find the hidden gem – the company poised for explosive growth?
That’s where our expertise comes in.
We’ve got the answer, but there’s a twist…
Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.
That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!
Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.
This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.
It’s like having a race car on a go-kart track.
They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.
Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.
We want to make sure none of our valued readers miss out on this groundbreaking opportunity!
That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%.
For a ridiculously low price of just $29, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!
Here’s why this is a deal you can’t afford to pass up:
• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.
• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.
• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149
• Bonus Reports: Premium access to members-only fund manager video interviews
• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
• 30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.
Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.
Here’s what to do next:
1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29.
2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.
3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.
Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!
No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a year later!
I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.
We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…
Should I put my money in Artificial Intelligence?
Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.
Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…
But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.
That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…
And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.
He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.
